Bryan Garnier - Osmozis (ALOSM.PA) OSMOZIS - BUY | EUR6.7(+26%) Steady Q3 revenues ahead of a promising Summer – company contact

Report

Bryan Garnier

Eric Lemarie

OSMOZIS - BUY | EUR6.7(+26%) Steady Q3 revenues ahead of a promising Summer – company contact

OSMOZIS - BUY | EUR6.7(+26%)
Steady Q3 revenues ahead of a promising Summer – company contact

Dynamic performance in Q3
The strong level of reservations of the market bodes well for Q4 activity
While materials and component inflation is not an issue today
Valuation and rating unchanged

30/06/2021 5 EN

Underlying

Osmozis

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Lemarie

Other Reports on these Companies

Bryan Garnier

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead Strong start of the year… … leading to revised estimates TP increased, investment case confirmed

January 14, 2022 January 14, 2022 1 EN

Bryan Garnier

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition Solid profitability in 2020-21 Transformation of the group under way Further growth expected this year with EBITDA margin of 33% at least Buy reiterated, on the back of a positive momentum

December 15, 2021 December 15, 2021 4 EN

Bryan Garnier

OSMOZIS: Strong FY EBITDA margin expected after a good summer. | BUY | EUR8 VS. EUR6.7 (+34%)

OSMOZIS - BUY | EUR8 VS. EUR6.7 (+34%) Strong FY EBITDA margin expected after a good summer. A dynamic summer EUR2.5m of EBITDA reachable this year Solid mid-term guidance

October 13, 2021 October 13, 2021 4 EN

On the shelves now: Consumer Weekly #67

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we look at the largest beauty groups in the world. Happy reading!

14h / 30m 14h / 30m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Kempower: Updating our model following Q1 results

Last Friday, Kempower published Q1 2025 results, reporting revenues of EUR43.5m (+2% YoY vs. EUR42.6m in Q1 2024), though revenues declined sequentially due to continued soft demand due to elevated inventory levels across the DC charging industry. Gross margin remained stable at 49.5% (-0.3ppt YoY)

17h / 30m 17h / 30m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Valneva: France suspends Ixchiq for >65yo pending investigation

Valneva's Ixchiq has been suspended by France's HAS (national public health agency) for the use in persons aged >65 y.o pending further investigation, after three cases of SAEs (all in patients >80, with one death) have been reported in the French pharmacovigilence database — these cases have

17h / 48m 17h / 48m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

OSMOZIS - BUY | EUR6.7(+26%) Steady Q3 revenues ahead of a promising Summer – company contact

OSMOZIS - BUY | EUR9.5 VS. EUR8.3 (+22%) Bright year ahead

OSMOZIS - BUY | EUR8.3 VS. EUR8 (+44%) Well placed to benefit from the energy and digital transition

OSMOZIS: Strong FY EBITDA margin expected after a good summer. | BUY | EUR8 VS. EUR6.7 (+34%)

On the shelves now: Consumer Weekly #67

Kempower: Updating our model following Q1 results

Valneva: France suspends Ixchiq for >65yo pending investigation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe